Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis

Blood Pressure
Michel BurnierPatrick Brunel

Abstract

Objective: Angiotensin receptor blockers (ARB) are among the recommended first-line treatment options in patients with hypertension and chronic kidney disease (CKD). This meta-analysis evaluated the effect of ARB on blood pressure (BP) and renal function in patients with concomitant hypertension and CKD with or without diabetes.Methods: Literature search was performed in PubMed/MEDLINE, EMBASE and BIOSIS to identify parallel-group, randomized controlled trials (≥8 weeks) reporting the effects of ARB on office systolic/diastolic BP (SBP/DBP), estimated glomerular filtration rate (eGFR), serum creatinine (SCr), creatinine clearance (CrCl) or proteinuria in adults with hypertension and CKD. Mean difference (MD, generic inverse variance) with 95% confidence intervals (CIs) was used to report an outcome.Results: Among the 24 studies identified, 19 evaluated ARB as monotherapy, 4 evaluated ARB as combination therapy and one evaluated ARB both as monotherapy and combination therapy. Median (range) duration of the studies was 12 (1.84-54.0) months. ARB monotherapy significantly (p < 0.01) reduced BP (treatment ≥1 year: SBP [MD: -14.84 mmHg; 95% CI: -17.82 to -11.85]/DBP [-10.27 mmHg; -12.26 to -8.27]) and proteinuria (≥1 year [-0.90 g/...Continue Reading

References

Feb 1, 1989·Kidney International·P C BrazyJ F Fitzwilliam
Jan 4, 1996·The New England Journal of Medicine·M J KlagJ Stamler
Mar 1, 1996·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·F LocatelliA Giangrande
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Apr 4, 2002·Psychological Methods·Scott B Morris, Richard P DeShon
Apr 17, 2002·Annals of Internal Medicine·Giuseppe RemuzziNorberto Perico
Sep 18, 2002·Kidney International·Matthew R Weir
Nov 21, 2002·JAMA : the Journal of the American Medical Association·Jackson T WrightUNKNOWN African American Study of Kidney Disease and Hypertension Study Group
Dec 6, 2002·Journal of the American Society of Nephrology : JASN·Ruth C CampbellGiuseppe Remuzzi
Jun 26, 2003·Archives of Internal Medicine·Henry T Yu
Aug 26, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Manuel PragaJose María Campistol
Sep 19, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Alexander V CrowePeter S Williams
Jan 13, 2004·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hiroto MatsudaTakao Saruta
Feb 3, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Robert C AtkinsEdmund J Lewis
Apr 26, 2005·Clinical Nephrology·A M SharmaUNKNOWN treated with Telmisartan (ESPRIT) Study Group
Aug 27, 2005·Journal of the American Society of Nephrology : JASN·Roland E SchmiederChristian Delles
Sep 15, 2005·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Tsukasa NakamuraUNKNOWN Efficacy of Candesartan on Outcome in Saitama Trial Group
Nov 29, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Pedro ArandaEduardo López de Novales
Jan 13, 2006·The New England Journal of Medicine·Fan Fan HouRen Wen Geng
Jan 20, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Csaba P KovesdyJohn E Anderson
Dec 23, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Pantelis A SarafidisGeorge L Bakris
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·William F KeaneUNKNOWN RENAAL Study Investigators
Sep 1, 2007·Journal of Hypertension·Norman K HollenbergRicardo Rocha
Aug 21, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Tsukasa NakamuraKoichi Node
Oct 11, 2008·Nature Reviews. Drug Discovery·Norberto PericoGiuseppe Remuzzi
Oct 16, 2008·Clinical and Experimental Hypertension : CHE·Tsukasa NakamuraKoichi Node
Feb 13, 2009·Journal of the American Society of Nephrology : JASN·Ellen BurgessUNKNOWN SMART (Supra Maximal Atacand Renal Trial) Investigators
Apr 3, 2009·Clinical Journal of the American Society of Nephrology : CJASN·Rajiv Agarwal
May 5, 2010·Nature Reviews. Nephrology·Piero RuggenentiGiuseppe Remuzzi
Jun 30, 2010·European Journal of Clinical Investigation·Tsukasa NakamuraHikaru Koide

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.